A Phase 1 First-in-Human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR441000 administered intratumorally as monotherapy and in combination with cemiplimab in patients with advanced solid tumors.

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT03871348

Study #:
STUDY00144273

Start Date:
Jan 01, 0001

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03871348

View Complete Trial Details & Eligibility at ClinicalTrials.gov